Phathom Pharmaceuticals Inc (PHAT)
10.27
-0.06
(-0.58%)
USD |
NASDAQ |
Jun 26, 14:29
Phathom Pharmaceuticals Enterprise Value: 432.63M for June 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 25, 2024 | 432.63M |
| June 24, 2024 | 459.56M |
| June 21, 2024 | 475.36M |
| June 20, 2024 | 518.09M |
| June 18, 2024 | 521.61M |
| June 17, 2024 | 511.66M |
| June 14, 2024 | 491.17M |
| June 13, 2024 | 467.75M |
| June 12, 2024 | 463.07M |
| June 11, 2024 | 472.44M |
| June 10, 2024 | 455.46M |
| June 07, 2024 | 447.27M |
| June 06, 2024 | 393.41M |
| June 05, 2024 | 430.29M |
| June 04, 2024 | 433.22M |
| June 03, 2024 | 431.46M |
| May 31, 2024 | 378.20M |
| May 30, 2024 | 423.27M |
| May 29, 2024 | 416.83M |
| May 28, 2024 | 429.12M |
| May 24, 2024 | 441.41M |
| May 23, 2024 | 429.71M |
| May 22, 2024 | 432.63M |
| May 21, 2024 | 454.88M |
| May 20, 2024 | 464.24M |
| Date | Value |
|---|---|
| May 17, 2024 | 443.76M |
| May 16, 2024 | 452.54M |
| May 15, 2024 | 436.15M |
| May 14, 2024 | 434.97M |
| May 13, 2024 | 392.83M |
| May 10, 2024 | 384.34M |
| May 09, 2024 | 417.41M |
| May 08, 2024 | 418.00M |
| May 07, 2024 | 426.19M |
| May 06, 2024 | 461.32M |
| May 03, 2024 | 414.38M |
| May 02, 2024 | 397.99M |
| May 01, 2024 | 368.73M |
| April 30, 2024 | 355.27M |
| April 29, 2024 | 373.99M |
| April 26, 2024 | 364.05M |
| April 25, 2024 | 359.36M |
| April 24, 2024 | 360.53M |
| April 23, 2024 | 357.02M |
| April 22, 2024 | 354.10M |
| April 19, 2024 | 351.76M |
| April 18, 2024 | 381.60M |
| April 17, 2024 | 400.33M |
| April 16, 2024 | 413.79M |
| April 15, 2024 | 413.21M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
116.44M
Minimum
Feb 13 2024
1.163B
Maximum
Jun 08 2020
564.80M
Average
532.01M
Median
Apr 09 2024
Enterprise Value Benchmarks
| Insmed Inc | 10.92B |
| Regeneron Pharmaceuticals Inc | 109.54B |
| Rocket Pharmaceuticals Inc | 1.835B |
| Rhythm Pharmaceuticals Inc | 2.408B |
| Xeris Biopharma Holdings Inc | 454.40M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -82.85M |
| Revenue (Quarterly) | 1.912M |
| Total Expenses (Quarterly) | 71.87M |
| EPS Diluted (Quarterly) | -1.42 |
| Gross Profit Margin (Quarterly) | 77.72% |
| Profit Margin (Quarterly) | -4.33K% |
| Earnings Yield | -43.52% |